A Phase Ib, Double-Blind, Randomized, Placebo-Controlled Trial in Genotype 1 HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of TMC649128 Given as Monotherapy and Given in Combination With Pegylated Interferon + Ribavirin.

Trial Profile

A Phase Ib, Double-Blind, Randomized, Placebo-Controlled Trial in Genotype 1 HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of TMC649128 Given as Monotherapy and Given in Combination With Pegylated Interferon + Ribavirin.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 Oct 2015

At a glance

  • Drugs TMC 649128 (Primary) ; Peginterferon; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Janssen Infectious Diseases BVBA
  • Most Recent Events

    • 13 Feb 2012 Company (Tibotec BVBA) added as trial sponsor as reported by ClinicalTrials.gov record (NCT01532557).
    • 13 Feb 2012 Company (Tibotec BVBA) added as trial sponsor as reported by ClinicalTrials.gov record (NCT01532557).
    • 16 Nov 2011 Status changed from recruiting to discontinued according to a Medivir media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top